CIOMS FORM

SUSPECT ADVERSE REACTION REPORT

DO-Tolmar-TLM-2025-01093

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE Years	3. SEX	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
		Day	Month	Year			Day	Month	Year	
MAAL	DOMINICAN Cont..	11	Nov	1960	64	Male		Oct	2024	

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) Spinal metastases (Metastases to spine (10027468), Metastases to spine (10027468)) (/Oct/2024 -) - Unknown
2) patient was not given the prescribed dose of Eligard on April 26, 2025, because he was receiving radiation therapy (Intentional dose omission (10079221), Intentional dose omission (10079221)) Unknown

Cont..

- ☐ PATIENT DIED
- ☑ LIFE THREATENING
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- ☐ RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- ☐ CONGENITAL ANOMALY
- ☑ OTHER MEDICALLY IMPORTANT CONDITION

II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (45 Milligram, Injection)(Unknown)

Cont..

20. DID EVENT ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☑ NA

15. DAILY DOSE(S)	16. ROUTE(S) OF ADMINISTRATION
1) (45 milligram(s), 1 in 6 Month)	1) Subcutaneous

21. DID EVENT REAPPEAR AFTER REINTRODUCTION ☐ YES ☐ NO ☑ NA

(NA : Not Applicable)

17. INDICATION(S) FOR USE

1) Prostate cancer [10060862 - Prostate cancer]

18. THERAPY DATE(S) (from/to)	19. THERAPY DURATION
(29-Oct-2024 - Ongoing)	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

1)INSULIN INSULIN NOS

Cont..

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes)

Cont..

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA
debbie.maierhofer@tolmar.comand+1-4129158447

Study Information
Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

24.REPORT NULLIFIED	24b. MFR CONTROL NO.
☐ YES ☐ NO	DO-Tolmar-TLM-2025-01093
24c. DATE RECEIVED BY MANUFACTURER: 28/Apr/2025	24d. REPORT SOURCE: ☑ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL
DATE OF THIS REPORT: 03/May/2025	25a. REPORT TYPE: ☑ INITIAL ☐ FOLLOWUP

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

1a. COUNTRY

DOMINICAN REPUBLIC

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

Event Description :

This study report from Dominican Republic was received by Adium (Reference number: DO-ADIUM-DO-0026-20250428) via Patient Support Program on 28-Apr-2025, from a consumer (patient's wife) regarding an adult 64-year-old male patient who experienced a serious event of ‘spinal metastases' (metastases to spine) (life threatening and medically significant) and 'patient was not given the prescribed dose of Eligard on 26-Apr-2025, because he was receiving radiation therapy' (Intentional dose omission) (non-serious) during Eligard (leuprolide acetate) 45 mg therapy for prostate cancer. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 29-Apr-2025.

The patient's medical history was unknown and current conditions included, prostate cancer, diabetes mellitus and hypertension.

Concomitant medications included insulin, metformin, Cardesertal (Cardiosertan-3) and radiation therapy.

On 29-Oct-2024, the patient began receiving Eligard 45 mg every 6 months via subcutaneous route for prostate cancer (Lot numbers and expiration dates were unknown).

On an unknown date in Oct-2024, the patient was diagnosed with prostate cancer that had metastasized to his spine.

On 14-Jan-2025, the patient's radiation therapy ended (received 40 radiation therapies).

On 26-April 2025, the patient was not given the prescribed dose of Eligard as he was receiving radiation therapy.

On 02-May-2025, the Eligard administration was rescheduled.

Corrective treatment included 40 radiation therapies.

Relevant test results included:
On an unknown date: Blood pressure: High blood pressure (Ref range: not provided)

Action taken with Eligard in response to event was dose not changed. De-challenge and re-challenge were not applicable.

The outcome of metastases to spine and Intentional dose omission was unknown.

The reporter assessed the seriousness of metastases to spine as serious (life threatening) and did not assess for intentional dose omission.

The reporter did not provide the causality of metastases to spine, intentional dose omission in relationship to Eligard and Eligard Unspecified Device.

No follow-up queries raised.

Listedness

Metastases to spine>Eligard>Listed as per CCDS>07-Nov-2024
Metastases to spine>Eligard>Listed as per USPI>Feb-2025
Metastases to spine>Eligard unspecified device>Listed as per USPI>Feb-2025
Metastases to spine>Eligard>Listed as per Canadian monograph>02-Apr-2025

Intentional dose omission>Eligard>Unlisted as per CCDS>07-Nov-2024
Intentional dose omission>Eligard>Unlisted as per USPI>Feb-2025
Intentional dose omission>Eligard unspecified device>Unlisted as per USPI>Feb-2025
Intentional dose omission>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

Company Remarks (Sender's Comments) :

Evaluator comment (Tolmar): This is regarding an adult 64-year-old male patient who had metastases to spine ('spinal metastases') and intentional dose omission ('patient was not given the prescribed dose of Eligard on 26-Apr-2025, because he was receiving radiation therapy') during 45 mg Eligard (Leuprolide acetate) therapy for prostate cancer. Tolmar assessed the event metastases to spine as serious (life threatening and IME) and intentional dose omission as non-serious since it does not meet the ICH seriousness criteria and is not an IME event. The reported event intentional dose omission was considered as not related (drug and device) as the event occurred with the product due to human action, rather due to the drug. The event metastases to spine was considered as not related (drug and device) as the event is attributed to underlying prostate cancer.

Additional Information (Continuation...)

Continuation Sheet for CIOMS report

Lab Result :

Test Name	Test Date	Test Result	Normal Value
BLOOD PRESSURE	Unknown		

Test Result (Code) / Result Unstructured Data (free text) :

1) Test Name: BLOOD PRESSURE

Result Unstructured Data (free text) : High blood pressure

Test Date: Unknown

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug : Eligard® (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form Strength : 1) 45 Milligram
Form of Admin : 1) Injection
Lot Number : 1) Unknown
Daily Dose : (45 milligram(s), 1 in 6 Month)
Route of Admin : 1) Subcutaneous
Indications : 1) Prostate cancer [10060862 - Prostate cancer]
Action(s) Taken With Drug : Dose not changed

Causality

1) Spinal metastases (Metastases to spine - 10027468, Metastases to spine - 10027468)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

2) patient was not given the prescribed dose of Eligard on April 26, 2025, because he was receiving radiation therapy (Intentional dose omission - 10079221, Intentional dose omission - 10079221)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Spinal metastases
CORE Labeled

2) patient was not given the prescribed dose of Eligard on April 26, 2025, because he was receiving radiation therapy
CORE UnLabeled

2) Drug : Eligard® Unspecified Device (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form of Admin : 1) Injection
Lot Number : 1) Unknown
Indications : 1) Prostate cancer [10060862 - Prostate cancer]
Action(s) Taken With Drug : Not applicable

Causality

1) Spinal metastases (Metastases to spine - 10027468, Metastases to spine - 10027468)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

2) patient was not given the prescribed dose of Eligard on April 26, 2025, because he was receiving radiation therapy (Intentional dose omission - 10079221, Intentional dose omission - 10079221)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Continuation Sheet for CIOMS report

Labeling :

1) Spinal metastases
CORE
2) patient was not given the prescribed dose of Eligard on April 26, 2025, because he was receiving radiation therapy
CORE

15. DAILY DOSE(S) (Continuation...)

Dosage Text :

22.CONCOMITANT DRUG(S) (Continuation...)

1). Drug	:	INSULIN [INSULIN NOS]
Active Substance	:	1) INSULIN NOS
Form Strength	:	
Daily Dose	:	1) 52.0 milligram(s) (26 milligram(s), 2 in 1 Day)
Indications	:	1) Diabetes [10012594 - Diabetes]

2). Drug	:	Metformin
Active Substance	:	1) METFORMIN
Form Strength	:	1) 800 Milligram
Daily Dose	:	1) 800.0 milligram(s) (800 milligram(s), 1 in 1 Day)
Indications	:	1) Diabetes [10012594 - Diabetes]

3). Drug	:	Cardesertal (Cardiosertan-3)
Active Substance	:	1) HYDROCHLOROTHIAZIDE
		2) AMLODIPINE BESILATE
		3) CANDESARTAN CILEXETIL
Form Strength	:	
Daily Dose	:	1) 32.0 milligram(s) (32 milligram(s), 1 in 24 Hour)
Indications	:	1) Hypertension [10020772 - Hypertension]

4). Drug	:	Radiation therapy
Active Substance	:	1) OTHER THERAPEUTIC PRODUCTS
Form Strength	:	
Indications	:	1) Spinal metastases [10041581 - Spinal metastases]
Dosage Text	:	1) Patient was not given the prescribed dose of Eligard on 26-Apr-2025 because he was receiving radiation therapy.

23. OTHER RELEVANT HISTORY (Continuation...)

2) HYPERTENSION (HIGH BLOOD PRESSURE) (10020772 , Hypertension) (Continuing : YES)

3) DIABETES (10012594 , Diabetes) (Continuing : YES)